What is the typical tirzepatide dose?
Clinical tirzepatide dose ranges span 2.5 mg starter doses through 15 mg per week maintenance doses, administered subcutaneously once weekly. The typical titration pattern starts at 2.5 mg for 4 weeks, then increases by 2.5 mg every 4 weeks based on tolerability toward the maintenance target.
What the research literature says
Tirzepatide’s clinical dose range was characterised across the SURPASS program for type 2 diabetes (SURPASS-4 vs insulin glargine, PMID 34672967; head-to-head against semaglutide in SURPASS-2, PMID 34170647) and the SURMOUNT program for obesity (SURMOUNT-2 in obesity with type 2 diabetes, PMID 37385275; SURMOUNT-4 weight-maintenance, PMID 38078870). The standard clinical-protocol pattern: start at 2.5 mg once weekly for 4 weeks, increase to 5 mg for 4 weeks, continue 4-week step-up to 7.5, 10, 12.5, or 15 mg per week target.
For type 2 diabetes the maintenance target is typically 5, 10, or 15 mg per week. For obesity management the maintenance target is typically 10 or 15 mg per week, with higher doses producing greater weight-reduction in dose-response analyses across the SURMOUNT trials.
The Frias head-to-head against semaglutide in type 2 diabetes patients documented superior glycemic and weight outcomes for tirzepatide at matched comparator doses (PMID 34170647), informing the broader research-protocol design framework. Research-supply protocols typically mirror the clinical titration pattern unless the experimental question requires deviation.
Why this matters in research context
The 4-week step-up titration pattern is critical for tirzepatide protocols specifically because the dual GIP + GLP-1 receptor pharmacology can produce dose-limiting GI tolerability issues at higher initiation doses. Researchers running tirzepatide protocols should follow the established clinical-titration cadence unless specific experimental design requires deviation. The reconstitution-volume choice should accommodate per-dose volumes across the full 2.5-15 mg range.
Related compounds
- Tirzepatide 10mg — the compound covered by this answer
Related research questions
- What is the half-life of tirzepatide?
- How much bacteriostatic water with tirzepatide?
- How does tirzepatide work?
References
- Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med 2021;385(6):503-515. [PMID 34170647]
- Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4). Lancet 2021;398(10313):1811-1824. [PMID 34672967]
- Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet 2023;402(10402):613-626. [PMID 37385275]
- Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA 2024;331(1):38-48. [PMID 38078870]
Research-questions pages describe research-context use of peptide-research terminology. They do not constitute medical, veterinary, or clinical advice. Tirzepatide is sold strictly as a research-grade reagent for laboratory and bench research applications.